BIOSENSE WEBSTER, INC (IRWINDALE) NOGA-STAR¿ CARDIOLOGY CATHETER; CATHETER, ELECTRODE RECORDING, OR PROBE, ELECTRODE RECORDING
|
Back to Search Results |
|
Model Number 120707S |
Device Problem
Insufficient Information (3190)
|
Patient Problems
Atrial Fibrillation (1729); Bradycardia (1751); Coagulation Disorder (1779); Death (1802); Swelling (2091); Electrolyte Imbalance (2196); Cardiogenic Shock (2262); Respiratory Failure (2484); No Code Available (3191)
|
Event Date 05/13/2015 |
Event Type
Death
|
Event Description
|
It was reported that the (b)(6) male patient had undergone the study procedure using nogastar catheter (lv mapping and endomyocardial stem cell therapy vs.Placebo) on (b)(6) 2015 which was a part of dream-hf clinical trial.The patient was in stable condition prior to being discharged from hospital.The patient admitted to a hospital again for leg swelling and generalized weakness but no association to fever, chills, pnd, orthopnea, or chest pain.Patient¿s problems at the time of visit included hyperkalemia, acute kidney injury, cardiogenic shock, atrial fibrillation, acute respiratory failure, hyponatremia, coagulopathy, and bradycardia.The patient had expired on (b)(6) 2015.There was no autopsy was requested.There were no complications related to the study procedure and no anomalies were found on the catheter during the case.The physician¿s opinion regarding the cause of this adverse event is that this is not procedure related.However, since the nogastar catheter was present during this procedure, bwi takes conservative approach and reports this event under the nogastar catheter.
|
|
Manufacturer Narrative
|
The device history record (dhr) was reviewed and no anomalies were found related to this complaint.In addition, the dhr review verifies that the device was manufactured in accordance with documented specification and procedures.(b)(6).(b)(4).
|
|
Manufacturer Narrative
|
(b)(4).It was reported that the (b)(6) male patient had undergone the study procedure using nogastar catheter (lv mapping and endomyocardial stem cell therapy vs.Placebo) on (b)(6) 15 which was a part of (b)(6) clinical trial.The patient was in stable condition prior to being discharged from hospital.The patient admitted to a hospital again for leg swelling and generalized weakness but no association to fever, chills, pnd, orthopnea, or chest pain.Patient¿s problems at the time of visit included hyperkalemia, acute kidney injury, cardiogenic shock, atrial fibrillation, acute respiratory failure, hyponatremia, coagulopathy, and bradycardia.The patient had expired on (b)(6) 2015.The returned device was visually inspected upon receipt and it was found in normal conditions.Per the event, the catheter was tested for electrical performance, temperature response and stockert compatibility and it was found within specifications.Furthermore, an irrigation test was performed and the catheter passed, no occlusion was observed.A deflection test was performed and the catheter passed.The catheter was also evaluated for carto 3.The catheter was recognized by carto 3 system, no error messages were displayed and the catheter was properly visualized.The force feature was evaluated and passed.The device history record (dhr) was reviewed and no anomalies were found related to this complaint.In addition, the dhr review verifies that the device was manufactured in accordance with documented specification and procedures.The catheter passed all specifications patient cause of decease remains unknown.
|
|
Manufacturer Narrative
|
The bwi failure analysis lab received the device for evaluation.The analysis has begun but is not completed at this time.When the investigational analysis has been completed, a supplemental 3500a report will be submitted.
|
|
Search Alerts/Recalls
|
|
|